Filing Flows › Regenerative Medical Technology Group (RMTG) › Q1 2026 › vs Q4 2025
Regenerative Medical Technology Group (RMTG) Q1 2026 vs Q4 2025 (quarter over quarter)
Regenerative Medical Technology Group's revenue rose $1.1M (+68%) from $1.6M in Q4 2025 to $2.6M in Q1 2026. The biggest changes: Product Supplies +$622K (+96%); Training +$305K (+65%); Patient Procedures +$208K (+53%).
Regenerative Medical Technology Group, Q1 2026: revenue $2.6M (+94% year over year), operating margin 8.7%, net loss $876K, operating cash flow $102K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Product Supplies | $1.3M | $645K | $622K | +96% |
| Training | $772K | $467K | $305K | +65% |
| Patient Procedures | $600K | $392K | $208K | +53% |
| Revenue | $2.6M | $1.6M | $1.1M | +68% |
| Net loss | $876K | $1.4M | −$517K | -37% |
| Costs & expenses | $3.5M | $3.0M | $551K | +19% |
| Operating costs | $2.4M | $1.9M | $531K | +28% |
| Interest & other, net | $1.1M | $1.1M | $19K | +2% |
| Cost of revenue | $873K | $792K | $80K | +10% |
| Sales & marketing | $391K | $182K | $209K | +115% |
| General & admin | $476K | $389K | $86K | +22% |
| Other operating costs | $670K | $514K | $156K | +30% |
| Operating cash sources | $978K | $1.4M | −$453K | -32% |
| Depreciation & amortization | $98K | $98K | −$1K | -0.7% |
| Working capital & other | $881K | $1.3M | −$452K | -34% |
| Net loss absorbed | $876K | $1.4M | −$517K | -37% |
| Operating cash flow | $102K | $38K | $64K | +167% |
| Capital expenditures | $315K | $267K | $48K | +18% |
| Negative free cash flow (OCF − capex) | $213K | $229K | −$16K | -7% |
Questions
How much did Regenerative Medical Technology Group's revenue grow quarter over quarter in Q1 2026?
Regenerative Medical Technology Group's revenue rose $1.1M (+68%) from $1.6M in Q4 2025 to $2.6M in Q1 2026.
What drove Regenerative Medical Technology Group's revenue change in Q1 2026?
Product Supplies +$622K (+96%); Training +$305K (+65%); Patient Procedures +$208K (+53%).